Pricing Strategies and Reimbursement

After UK apixaban prices started to creep up in July, the latest WaveData figures show several different presentations of the generic increasing their average price by multiples in August.

In a frank acknowledgement of Sandoz’s position in the US small-molecule generics market, the company’s North America president Keren Haruvi has indicated that the firm is “not looking to be a leader in the generics space” and is still suffering from a lack of investment made in its pipeline during the period several years ago when it was looking to sell the oral solids business.

Glenmark Pharmaceuticals has agreed a $25m payout in the US to resolve its alleged liability under the False Claims Act linked to historical price-fixing allegations.

The latest figures on uptake for rivals to Humira in the US show adalimumab biosimilars beginning to capture significant market share from the originator, AbbVie’s Humira, after an initially slow start in 2023.

July’s UK generic pricing figures from WaveData show captopril tablets rocketing up in price, while aripiprazole prices continue to plummet.

Boehringer Ingelheim is partnering with GoodRx in the US to offer a version of its Humira biosimilar at a 92% discount to the brand’s list price. Generics Bulletin spoke with Chris Marsh, Boehringer’s senior vice president of value and access, about the initiative.

The latest UK generic pricing information from WaveData shows multiple products doubling or even trebling their average prices in June.

Almost a year after launching Celltrion’s Yuflyma rival to Humira in the US, Tom Nusbickel, chief commercial officer of Celltrion USA, reflects on experiences in the market so far and key launches on the horizon, in an exclusive interview with Generics Bulletin.

With a fresh pricing deal on the horizon, Medicines for Ireland chair and Teva country head Paul Neill talks to Generics Bulletin about the need for the Irish off-patent industry to have “a true seat at the table” and secure an agreement with the country’s government that better reflects the specificities of the generics and biosimilars market.

Global biosimilars player Pfizer is calling for a more sustainable approach to the market to ensure its long-term viability. In the second part of an exclusive interview, Barry Chester, the firm’s global commercial lead for supportive care oncology, tells Generics Bulletin where the company sees room for improvement.

Pfizer is one of the leading players in the global biosimilars market. Barry Chester, the firm’s global commercial lead for supportive care oncology, talks to Generics Bulletin about how the business fits into the firm’s wider interests, in the first part of an exclusive interview.

Pregabalin topped our table of Biggest Risers in May, in another month of multiple treble-digit-percentage average price increases for the UK generics market.

With UK shortages and price rises making headlines in early 2024, April’s generic pricing data suggested an easing of pricing increases, according to the latest figures from WaveData.

Despite receiving mixed opinions on the Medicare Part D final rule, CMS sees support from the off-patent group AAM, which said that the new policy will have an “immediate impact” on cost reduction and increased access to biosimilars.

 The US off-patent association published an analysis of IQVIA data, which highlights the role of rebate schemes that is slowing the adoption of Humira biosimilars that would save billions of dollars.

The timing of the request, with Xtandi’s loss of exclusivity on the horizon, could be explained by the concern that a change in the US presidential administration in 2025 may limit the prospects for near-term relief.